Comparative study of common methods for vision restoration
DOI:
https://doi.org/10.61173/qc3zm321Keywords:
Vision restoration, Retinal degeneration, Invasive, non-InvasiveAbstract
Vision impairment is a major global health issue that affects more than two billion people and causes large economic losses. Therapies for it have been developed during the past few decades. This research summarizes common methods for vision restoration. Invasive methods include gene therapy, cell therapy, and retinal prostheses. They often show stronger effects while having problems like high cost and safety concerns. Non-invasive methods include electromagnetic stimulation and drug delivery. These approaches are generally safer, cheaper, and easier for patients to accept, but their efficiency is usually limited, especially in late stages. The paper reviews the mechanism of each method, evidence of effectiveness, remaining challenges, and potential improvements in the future. It highlights that no single method can fully restore natural vision; combining approaches may offer better solutions in the future. It also stresses the importance of comparing these methods to guide future research. By doing this, the paper provides a clear picture of current progress and possible directions for vision restoration.
References
[1] World Health Organization. Blindness and vision impairment[R]. 2023-08-10.
[2] Cehajic-Kapetanovic J, Singh M S, Zrenner E, et al. Bioengineering strategies for restoring vision[J]. Nature Biomedical Engineering, 2023, 7: 387-404.
[3] Aleman T S, Miller A J, Maguire K H, et al. A virtual reality orientation and mobility test for inherited retinal degenerations: Dean&Francis ISSN 2959-409X testing a proof-of-concept after gene therapy[J]. Clinical Ophthalmology, 2021, 15: 939-952.
[4] Darrow J J. Luxturna: FDA documents reveal the value of a costly gene therapy[J]. Drug Discovery Today, 2019, 24(4): 949- 954.
[5] Pierce E A, Aleman T S, Jayasundera K T, et al. Gene editing for CEP290-associated retinal degeneration[J]. New England Journal of Medicine, 2024, 390: 1972-1984.
[6] Viral Kansara, Leroy Muya, Chen-rei Wan, et al. Suprachoroidal Delivery of Viral and Nonviral Gene Therapy for Retinal Diseases[J]. Journal of Ocular Pharmacology and Therapeutics, 2020 36(6): 384-392.
[7] Kansara V, Muya L, Wan C, et al. Suprachoroidal delivery of viral and nonviral gene therapy for retinal diseases[J]. Journal of Ocular Pharmacology and Therapeutics, 2020, 36.
[8] Hinkle J W, Mahmoudzadeh R, Kuriyan A E. Cell-based therapies for retinal diseases: a review of clinical trials and direct-to-consumer cell therapy clinics[J]. Stem Cell Research & Therapy, 2021, 12: 538.
[9] Allen P J. Retinal prostheses: where to from here[J]. Clinical and Experimental Ophthalmology, 2021, 49: 418-429.
[10] Li J, Zhou W, Liang L, et al. Noninvasive electrical stimulation as a neuroprotective strategy in retinal diseases: a systematic review of preclinical studies[J]. Journal of Translational Medicine, 2024, 22: 28.
[11] Perin C, Viganò B, Piscitelli D, et al. Non-invasive current stimulation in vision recovery: a review of the literature[J]. Restorative Neurology and Neuroscience, 2019, 38(3): 239-250.
[12] Himawan E, Ekström P, Buzgo M, et al. Drug delivery to retinal photoreceptors[J]. Drug Discovery Today, 2019, 24(8): 1637-1643.
Downloads
Published
Issue
Section
License
Copyright (c) 2025 by the authors.

This work is licensed under a Creative Commons Attribution 4.0 International License.
